These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37349816)

  • 1. Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa.
    Beesham I; Milford C; Smit J; Joseph Davey DL; Baeten JM; Heffron R; Beksinska M; Mansoor LE
    BMC Public Health; 2023 Jun; 23(1):1210. PubMed ID: 37349816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key stakeholders' perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa.
    Beesham I; Milford C; Joseph Davey DL; Smit J; Mansoor LE; Beksinska M
    Afr J AIDS Res; 2023 Apr; 22(1):18-26. PubMed ID: 36951406
    [No Abstract]   [Full Text] [Related]  

  • 3. Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial.
    Beesham I; Heffron R; Evans S; Baeten JM; Smit J; Beksinska M; Mansoor LE
    AIDS Behav; 2021 Apr; 25(4):1112-1119. PubMed ID: 33106996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.
    Beesham I; Joseph Davey DL; Beksinska M; Bosman S; Smit J; Mansoor LE
    AIDS Behav; 2022 Aug; 26(8):2623-2631. PubMed ID: 35122575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
    Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Donnell D; Baeten JM;
    J Int AIDS Soc; 2020 May; 23(5):e25491. PubMed ID: 32396700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring adolescent girls and young women's PrEP-user profiles: qualitative insights into differentiated PrEP delivery platform selection and engagement in Cape Town, South Africa.
    Rousseau E; Sikkema KJ; Julies RF; Mazer K; O'Malley G; Heffron R; Morton JF; Johnson R; Celum C; Baeten JM; Bekker LG
    J Int AIDS Soc; 2024 May; 27(5):e26254. PubMed ID: 38695101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experiences of oral pre-exposure prophylaxis use among heterosexual men accessing sexual and reproductive health services in South Africa: a qualitative study.
    Cholo FA; Dada S; Martin CE; Mullick S
    J Int AIDS Soc; 2024 May; 27(5):e26249. PubMed ID: 38695102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
    Beesham I; Mansoor LE; Joseph Davey DL; Palanee-Phillips T; Smit J; Ahmed K; Selepe P; Louw C; Singata-Madliki M; Kotze P; Heffron R; Parikh UM; Wiesner L; Rees H; Baeten JM; Beksinska M
    J Acquir Immune Defic Syndr; 2022 Sep; 91(1):26-30. PubMed ID: 35972853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stigma in the health clinic and implications for PrEP access and use by adolescent girls and young women: conflicting perspectives in South Africa.
    Nyblade L; Ndirangu JW; Speizer IS; Browne FA; Bonner CP; Minnis A; Kline TL; Ahmed K; Howard BN; Cox EN; Rinderle A; Wechsberg WM
    BMC Public Health; 2022 Oct; 22(1):1916. PubMed ID: 36242000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosocial determinants of pre-exposure prophylaxis use among pregnant adolescent girls and young women in Cape Town, South Africa: A qualitative study.
    Haribhai S; Khadka N; Mvududu R; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
    Int J STD AIDS; 2023 Jul; 34(8):548-556. PubMed ID: 36947792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors that influence adolescent girls and young women's re-initiation or complete discontinuation from daily oral PrEP use: a qualitative study from Eastern Cape Province, South Africa.
    de Vos L; Mudzingwa EK; Fynn L; Atujuna M; Mugore M; Gandhi M; Celum C; Hosek S; Bekker LG; Daniels J; Medina-Marino A
    J Int AIDS Soc; 2023 Sep; 26(9):e26175. PubMed ID: 37758649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
    Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
    J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to Oral HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Pregnant and Post-partum Women from Cape Town, South Africa.
    Beesham I; Dovel K; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
    AIDS Behav; 2022 Sep; 26(9):3079-3087. PubMed ID: 35316471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa-study protocol.
    Medina-Marino A; Bezuidenhout D; Hosek S; Barnabas RV; Atujuna M; Bezuidenhout C; Ngwepe P; Peters RPH; Little F; Celum CL; Daniels J; Bekker LG
    Trials; 2021 Jul; 22(1):489. PubMed ID: 34311754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strengthening health system's capacity for pre-exposure prophylaxis for adolescent girls and young women and adolescent boys and young men in South Africa (SHeS'Cap-PrEP): Protocol for a mixed methods study in KwaZulu-Natal, South Africa.
    Nicol E; Ramraj T; Hlongwa M; Basera W; Jama N; Lombard C; McClinton-Appollis T; Govindasamy D; Pass D; Funani N; Aheron S; Paredes-Vincent A; Drummond J; Cheyip M; Dladla S; Bedford J; Mathews C
    PLoS One; 2022; 17(3):e0264808. PubMed ID: 35298487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stepped care to optimize pre-exposure prophylaxis (PrEP) effectiveness in pregnant and postpartum women (SCOPE-PP) in South Africa: a randomized control trial.
    Joseph Davey DL; Dovel K; Cleary S; Khadka N; Mashele N; Silliman M; Mvududu R; Nyemba DC; Coates TJ; Myer L
    BMC Public Health; 2022 Jul; 22(1):1306. PubMed ID: 35799121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceptability and feasibility of leveraging community-based HIV counselling and testing platforms for same-day oral PrEP initiation among adolescent girls and young women in Eastern Cape, South Africa.
    Medina-Marino A; Bezuidenhout D; Ngwepe P; Bezuidenhout C; Facente SN; Mabandla S; Hosek S; Little F; Celum CL; Bekker LG
    J Int AIDS Soc; 2022 Jul; 25(7):e25968. PubMed ID: 35872602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing uptake, continuation, and discontinuation of oral PrEP among clients at sex worker and MSM facilities in South Africa.
    Pillay D; Stankevitz K; Lanham M; Ridgeway K; Murire M; Briedenhann E; Jenkins S; Subedar H; Hoke T; Mullick S
    PLoS One; 2020; 15(4):e0228620. PubMed ID: 32352969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.
    Donnell D; Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Rees H; Baeten JM;
    Lancet HIV; 2021 Aug; 8(8):e495-e501. PubMed ID: 34126052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.